Veronique Angeli National University of Singapore Singapore

SYMPOSIUM 4 Role of LYVE-1+ macrophage in arterial diseases

Hidenori Arai National Center for Geriatrics and Gerontology Japan

SYMPOSIUM 10 Update of lipid-lowering therapy guidelines; difference and similarity

Martin Bennett University of Cambridge UK

PLENARY LECTURE 6 Targeting smooth muscle cell in management of atherosclerotic cardiovascular disease

Dirk Blom Hatter Institute for Cardiovascular Research in Africa South Africa

SYMPOSIUM 20 Current trend in treatment of HeFH/HoFH

Karin Bornfeldt University of Washington USA

SYMPOSIUM 13 New insights from mouse models of diabetes-accelerated atherosclerosis

Jae-Hoon Choi Hanyang University Korea

SYMPOSIUM 4 Myeloid cell heterogeneity in hyperlipidemic cardiovascular diseases

So-Yeon Choi Ajou University Korea

SYMPOSIUM 7 Update on invasive imaging of vulnerable plaque

SungHee Choi Seoul National University Korea

SYMPOSIUM 10 Is current LDL-C target achievable?

Mete Civelek University of Virginia USA

SYMPOSIUM 3 How can we derive biological relevance from genetic studies on atherosclerosis?

Arnonld von Eckardstein University of Zürich Switzerland

SYMPOSIUM 21 Beyond HDL-cholesterol: the search for functional biomarkers of HDL

Edward A. Fisher NYU Grossman School of Medicine USA

SYMPOSIUM 4 Role of immune cells in the regression of atherosclerosis: conversations between fat and the plaque

Masato Furuhashi Sapporo University Japan

SYMPOSIUM 12 FABP as therapeutic target in ASCVD

Gwang-woong Go Hanyang University Korea

SYMPOSIUM 9 Dietary n-6 polyunsaturated fatty acids (n-6 PUFA) on health: a systematic review of clinical studies in 2014-2019

Ki Hoon Han University of Ulsan Korea

SYMPOSIUM 6 Is remnant lipoprotein atherogenic?

Sung Nim Han Seoul National University Korea

SYMPOSIUM 9 Dietary cholesterol recommendation for cardiovascular risk

Hiroyuki Hao Nihon University Japan

SYMPOSIUM 18 (Joint with JAS) Update on pathophysiology of acute coronary syndrome

Mariko Harada-Shiba National Cerebral and Cardiovascular Center Research Institute Japan

SYMPOSIUM 11 (Joint with IAS) Is it worth to adjust lipid-lowering therapy by ethnicity & how?

Kyung-Sun Heo Chungnam National University Korea

SYMPOSIUM 8 Update on endothelial cell as target of anti-atherosclerosis treatment

Jung Ho Heo Kosin University Korea

SYMPOSIUM 19 Anti-inflammatory treatment to reduce CV risk

Ken-ichi Hirata Kobe University Japan

PLENARY LECTURE 3 Optimal medical therapy to inhibit coronary plaque

Soon Jun Hong Korea University Korea

SYMPOSIUM 18 (Joint with JAS) Latest therapeutic strategies to modify platelet function

Hisanori Horiuchi Tohoku University Japan

SYMPOSIUM 18 (Joint with JAS) Topics in the antiplatelet therapy: Daily dose of thienopyridine ADP receptor antagonists in Japan and the effect of thrombocytopenia on the DAPT therapy

Mahmood Hussain New York University USA

SYMPOSIUM 16 Regulation of microsomal triglyceride transfer protein (MTP) in lipid metabolism

Byeong Hwa Jeon Chungnam National University Korea

SYMPOSIUM 5 Biological Role of APE1/Ref-1 in Vascular Calcification

Hanjoong Jo Emory University USA

SYMPOSIUM 8 Disturbed Flow Induces Endothelial Reprograming and Atherosclerosis. Lessons from single-cell RNAseq and ATACseq study

Jenny E. Kanter University of Washington USA

SYMPOSIUM 16 Apolipoprotein C3 as a regulator of triglyceride-rich lipoproteins in diabetes and its complications

Chang-Yeon Kim Daegu Catholic University Korea

SYMPOSIUM 2 Integration of new imaging or biomarkers to risk calculators

Jin-Won Kim Korea University Korea

SYMPOSIUM 7 Latest target molecules in imaging early & late atherosclerosis

Ji Yeon Kim Seoul National University of Science and Technology Korea

SYMPOSIUM 9 Dietary fiber and dyslipidemia

Kyung-Gon Kim University of Ulsan Korea

SYMPOSIUM 13 Proteomic studies in atherosclerotic cardiovascular disease

Mi Kyung Kim Inje University Korea

SYMPOSIUM 14 Biological effect & clinical benefit of omega-3 PUFA

Sang Yong Kim Chosun University Korea

SYMPOSIUM 15 New PPARalpha agonist

Sang-Hyun Kim Seoul National University Korea

SYMPOSIUM 20 Upcoming treatment agents for FH

Young-Kook Kim Chonnam National University Korea

SYMPOSIUM 22 The role of non-coding RNAs in vascular smooth muscle cells

Sin-Gon Kim Korea University Korea

SYMPOSIUM 11 (Joint with IAS) Timing & candidate of combination treatment

Bo Kyung Koo Seoul National University Korea

SYMPOSIUM 1 Heterogeneity of NAFLD from the perspective of atherosclerosis

Masahiro Koseki Osaka University Japan

SYMPOSIUM 1 NAFLD, NASH & cardiovascular disease

Seung-Hwan Lee The Catholic University of Korea Korea

SYMPOSIUM 2 Risk model for CV risk assessment in Korean population

Jong-Young Lee Sungkyunkwan University Korea

SYMPOSIUM 10 Is current stratification of very-high risk group appropriate?

Do Yup Lee Seoul National University Korea

SYMPOSIUM 13 Fatty liver disease and gut ecosystem: microbiome and metabolome

Yujin Lee Myongji University Korea

SYMPOSIUM 17 Nutrition policies to improve diet and reduce health and economic burdens of cardiometabolic diseases: a microsimulation study

Jang Hoon Lee Kyungpook National University Korea

SYMPOSIUM 21 What’s new in HDL-modifying therapeutics?

Klaus Ley La Jolla Institute for Immunology USA

PLENARY LECTURE 2 Single cell RNA and antibody sequencing in women and men with cardiovascular disease

Soo Lim Seoul National University Korea

SYMPOSIUM 12 Mechanism of vascular complications in obesity & metabolic syndrome

Ichiro Manabe Chiba University Japan

SYMPOSIUM 12 Immunometabolic control in macrophages

Jung-joon Min Chonnam National University Korea

SYMPOSIUM 7 Molecular imaging in atherosclerosis

Samia Mora Brigham and Women's Hospital, Harvard Medical School USA

SYMPOSIUM 11 (Joint with IAS) Optimal treatment & LDL-C target for intermediate/low risk population

Kiran Musunuru University of Pennsylvania USA

PLENARY LECTURE 5 Genetics/epigenetic approach in studies of lipid metabolism & atherosclerosis

Chang Seon Myung Chungnam National University Korea

SYMPOSIUM 5 Phenotypic changes of VSMC in atherosclerosis

Pradeep Natarajan Harvard Medical School USA

SYMPOSIUM 3 Mapping genetic associations to novel therapeutics for cardiometabolic disease

Ian Neeland University Hospitals Cleveland Medical Center USA

SYMPOSIUM 2 Understanding cardiovascular risk: using risk scores and other risk-based testing in the contemporary era

Masatsune Ogura Chiba University Graduate School of Medicine Japan

SYMPOSIUM 14 Latest data on siRNA against PCSK9

Goo Taeg Oh Ewha Womans University Korea

SYMPOSIUM 8 The Roles of peroxiredoxins in the pathogenesis of atherosclerosis

Koh Ono Kyoto University Japan

SYMPOSIUM 22 Function of miR-33a/b in lipid and systemic metabolism

Sung Ho Park UNIST Korea

SYMPOSIUM 3 Clinical implication of recent epigenetic studies on CAD & dyslipidemia

Hun-Jun Park The Catholic University of Korea Korea

SYMPOSIUM 15 Emerging targets for management of dyslipidemia

Young Mi Park Ewha Womans University Korea

SYMPOSIUM 16 What's new in intracellular lipid trafficking

Clara Yongjoo Park Chonnam National University Korea

SYMPOSIUM 17 Vitamin D in cardiometabolic disease - the more the better?

Kausik Ray Imperial College London UK

SYMPOSIUM 14 Patient selection for PCSK9 MAb based therapies

Katey Rayner University of Ottawa Canada

SYMPOSIUM 22 Non-coding RNA control of cholesterol metabolism and atherosclerosis

Alan Remaley National Institute of Health USA

PLENARY LECTURE 4 Hypertriglyceridemia: diagnostic and therapeutic implications

Gissette Reyes-Soffer Columbia University USA

SYMPOSIUM 15 The metabolic effects of antisense oligonucleotides treatments in dyslipidemia

Raul D. Santos University of Sao Paulo Brazil

PLENARY LECTURE 1 What’s new in epidemiology of atherosclerotic cardiovascular disease and its risk factors

Min-Jeong Shin Korea University Korea

SYMPOSIUM 9 Sodium dietary reference intakes based on CV disease

Judith C. Sluimer Maastricht University Netherlands

SYMPOSIUM 5 Cellular plasticity in atherosclerosis

Nathan Stitziel University of Washington USA

SYMPOSIUM 6 Targeting ANGPTL3 to reduce LDL cholesterol, triglyceride-rich lipoproteins, and cardiovascular disease

Hayato Tada Kanazawa University Japan

SYMPOSIUM 20 Personalized medicine for patients with FH

Sotirios Tsimikas University of California San Diego USA

SYMPOSIUM 19 Recent results on Lp(a) therapeutics

Tomas Vaisar University of Washington USA

SYMPOSIUM 21 HDL and the cardiovascular risk in diabetes

Marit Westerterp University of Groningen Netherlands

SYMPOSIUM 1 Leukocytes, inflammation, and atherosclerosis

Hong Xue George Mason University USA

SYMPOSIUM 17 Systems science in biomedical research regarding obesity and noncommunicable chronic diseases

Hye-Jin Yoo Korea University Korea

SYMPOSIUM 6 New therapeutics based on TG metabolism

Hiroshi Yoshida Jikei University School of Medicine Japan

SYMPOSIUM 19 Lp(a) as a risk factor